These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49 related articles for article (PubMed ID: 23495686)
21. The emerging role of low-molecular-weight heparin in cardiovascular medicine. Hirsh J; Bates SM Prog Cardiovasc Dis; 2000; 42(4):235-46. PubMed ID: 10661777 [TBL] [Abstract][Full Text] [Related]
22. Not Just Anticoagulation-New and Old Applications of Heparin. Zang L; Zhu H; Wang K; Liu Y; Yu F; Zhao W Molecules; 2022 Oct; 27(20):. PubMed ID: 36296562 [TBL] [Abstract][Full Text] [Related]
23. Heparin and low molecular weight heparin in thrombosis and beyond. Mousa SA Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411 [TBL] [Abstract][Full Text] [Related]
24. Cardiovascular autophagy: crossroads of pathology, pharmacology and toxicology. Salabei JK; Conklin DJ Cardiovasc Toxicol; 2013 Sep; 13(3):220-9. PubMed ID: 23408289 [TBL] [Abstract][Full Text] [Related]
26. Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. Erusalimsky JD; Kurz DJ Exp Gerontol; 2005; 40(8-9):634-42. PubMed ID: 15970413 [TBL] [Abstract][Full Text] [Related]
27. Heparin as an anticancer therapeutic. Zacharski LR; Lee AY Expert Opin Investig Drugs; 2008 Jul; 17(7):1029-37. PubMed ID: 18549339 [TBL] [Abstract][Full Text] [Related]
28. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Mousa SA Semin Thromb Hemost; 2007 Jul; 33(5):524-33. PubMed ID: 17629850 [TBL] [Abstract][Full Text] [Related]
29. [Effect of nonsteroidal anti-inflammatory agents on the cardiovascular system]. Stepaniuk GI; Stoliarchuk AA Farmakol Toksikol; 1987; 50(5):89-93. PubMed ID: 3319688 [No Abstract] [Full Text] [Related]
31. [Low molecular weight heparin in venous thromboembolism. Mechanism of action, therapy and prophylaxis]. Stammler F; Diehm C Dtsch Med Wochenschr; 1998 May; 123(19):604-11. PubMed ID: 9618643 [No Abstract] [Full Text] [Related]
32. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143 [TBL] [Abstract][Full Text] [Related]
33. Deep vein thrombosis and anticoagulant therapy. Sullano MA; Ortiz EJ Nurs Clin North Am; 2001 Dec; 36(4):645-63, v. PubMed ID: 11726345 [TBL] [Abstract][Full Text] [Related]
34. Blood clotting, inflammation, and thrombosis in cardiovascular events: perspectives. Boos CJ; Lip GY Front Biosci; 2006 Jan; 11():328-36. PubMed ID: 16146734 [TBL] [Abstract][Full Text] [Related]
35. [Pharmacologic study of the cardiovascular system in the Societ Ukraine over 50 years]. Trinus FP Farmakol Toksikol; 1967; 30(6):646-53. PubMed ID: 4386296 [No Abstract] [Full Text] [Related]
36. Old and new heparins. Cosmi B; Palareti G Thromb Res; 2012 Mar; 129(3):388-91. PubMed ID: 22137740 [TBL] [Abstract][Full Text] [Related]
37. Synthetic heparin derivatives as new anticoagulant drugs. de Kort M; Buijsman RC; van Boeckel CA Drug Discov Today; 2005 Jun; 10(11):769-79. PubMed ID: 15922935 [TBL] [Abstract][Full Text] [Related]
38. Is mycophenolate more than just an immunosuppressant?--An overview. Iyer A; Brown L Indian J Biochem Biophys; 2009 Feb; 46(1):25-30. PubMed ID: 19374250 [TBL] [Abstract][Full Text] [Related]
39. Building a better heparin. Caughey GH Am J Respir Cell Mol Biol; 2003 Feb; 28(2):129-32. PubMed ID: 12540478 [No Abstract] [Full Text] [Related]
40. Cardiovascular effects of NSAIDs. Sherve K; Gerard CJ; Neher JO; St Anna L Am Fam Physician; 2014 Aug; 90(4):Online. PubMed ID: 25251008 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]